Biohaven says FDA placed partial clinical hold on BHV-7000 enrollment
Biohaven Ltd. said the FDA put a partial clinical hold on BHV-7000 enrollment after a rodent metabolite finding. The company also said it shared related data with SK Biopharma under a licensing deal that could total $795M plus royalties.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.